Publikationen der Klinik für Strahlentherapie und Onkologie

Hier finden Sie die Publikationen der Klinik für Strahlentherapie und Onkologie der letzten Jahre.

Publikationen 2020

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD. Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations. Z Gastroenterol 2020;58:577-582.(Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol  2020; epub ahead of print (Pubmed-Link).

Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rödel C, Hautmann MG, Kölbl O, Salay A, Rübe C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P, PacCis-Study Group.. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial, Radiother Oncol 2020;144:209-217. (Pubmed-Link).

Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020 ;21:e252-e264. (Pubmed Link).

Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E, Claus Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:E1235. (Pubmed-Link).

Gaipl U, Multhoff G, Pockley G, Rödel F.  Editorial: Radioimmunotherapy—Translational Opportunities and Challenges. Front Oncol 2020;10:190. (Pubmed-Link).

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gikka E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke. MERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics J. 2020;epub ahead of print. (Pubmed-Link)

Kesara N, Winkelmann R, Oppermann J, Ghanaati S, Neumayer T, Martin D, Rödel C, Rödel F, von der Grün J, Balermpas P. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncology 2020;111:104931 epub ahead of print (Pubmed-Link).

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2020;112:211-213. (Pubmed-Link).

Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;149:168-73. (Pubmed-Link).

Martin D, von der Grün J, Rödel C, Fokas E. Management of anal cancer patients - a pattern of care analysis in German-speaking countries. Radiat Oncol 2020;15:122. (Pubmed-Link).

Martin D, Rödel C, Fokas E. Influence of treatment compliance on the success of chemoradiotherapy for anal carcinoma. Strahlenther Onkol 2020; epub ahead of print. (Pubmed-Link)

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49. (Pubmed-Link).

Martin D, von der Grün J, Rödel C, Fokas E. Sarcopenia is associated with hematologic toxicity during chemoradiotherapy in patients with anal carcinoma. Frontiers in Oncology 2020;10:1576. (Pubmed-Link)

Michaelis M, Voges Y, Rothweiler F, Weipert F, von Deimling A, Westermann F, Rödel F, Wassa M, Cinatl J. Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines. Cancers 2020;12:E577. (Pubmed-Link).

Michaelis M, Wass M, Reddin I, VogesY, RothweilerF, Hehlgans S, MernbergerM, NistA, Stiewe T, Rödel F, Cinatl J. Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of specific biomarkers for the acquired resistance setting, Cancers 2020;12:E1080. (Pubmed-Link).

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maignon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020 epub ahead of print (Pubmed-Link).

Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR Jr, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer 2020 ;136:176-185. (Pubmed-Link)

Rödel F, Arenas M, Ott O, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: What are the evidences? Strahlenther Onkol 2020;196:679-682. (Pubmed-Link).

Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, Seitz A, Kübler H, Flentje M, Chun F, Combs SE, Schiller K, Gschwend JE, Retz M. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer 2020;20:8. (Pubmed-Link).

Schmidt S, Linge A, Großer M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemo- therapy in head and neck squamous cell carcinoma. J Mol Diagn 2020;22:801-10 (Pubmed-Link).

Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML, Baus WW, Moustakis C. Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.  Strahlenther Onkol 2020,196:421-43. (Pubmed-Link)

Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progres